Legends of the Posterior Segment

Blair Lonsberry, MS, OD, MEd., FAAO
Professor of Optometry
Pacific University College of Optometry
blonsberry@pacificu.edu

Pacific University Oregon

Disclosures

Paid consultant for:

Maculogix: Honoraria-Advisory Board

Sun Pharmaceuticals: Advisory Board/Speakers Bureau

Pacific University Oregon

Case History

- 38 black male, complaining that the vision in his right eye is blurry.
  - Got the current Rx 3 weeks previously, and started out good but in last couple of days OD vision has become blurry
- Medical Hx: no current health concerns and no medications

Pacific University Oregon

Entrance Skills

- *Va's: OD: 20/25, OS: 20/20*
- *Pupils: PERRL*
- *CVF: full to finger count*
- *EOM's: FROM*
- *Amsler: central metamorphopsia OD*
- *HVF: 10-2 (see VF)*

Pacific University Oregon

SINGLE FIELD ANALYSIS

EYE: RIGHT

NAME: [redacted]

ID: 110724

DOB: 03-08-1969

CENTRAL 10-2 THRESHOLD TEST

FIXATION MONITOR: GAZE/BLINDSPOT
FIXATION TARGET: CENTRAL
FIXATION LOSSES: 2/15
FALSE POS ERRORS: 0 %
FALSE NEG ERRORS: 0 %
TEST DURATION: 06:32

FOVEA: OFF

STIMULUS: III, WHITE
BACKGROUND: 31.5 ASB
STRATEGY: SITA-STANDARD

PUPIL DIAMETER: 5.5 MM
VISUAL ACUITY:
RX: +4.00 DS -2.00 DC X 115

DATE: 09-19-2007
TIME: 10:07 AM
AGE: 38





TOTAL DEVIATION

PATTERN DEVIATION

MD -3.12 DB P < 2%
PSD 2.60 DB P < 1%

: < 5%
% < 2%
% < 1%

PACIFIC UNIVERSITY FAMILY EYE CENTER
511 SW 10TH AVE
PORTLAND, OR

Which of the following OCT's goes with this patient?

1



2



3



4





What would you recommend in the management of this patient?

1. Monitor
2. Topical NSAIDS
3. Focal laser
4. Anti-VEGF injection
5. Low intensity PDT
6. Topical steroid
7. Eplerenone

Central Serous Retinopathy

- an exudative chorioretinopathy characterized by an exudative neurosensory retinal detachment with or without an associated detachment of the retinal pigment epithelium (RPE)
- Patients experience blurry vision, metamorphopsia and micropsia
- individuals between 20 and 50 years of age

Central Serous Retinopathy

- incidence in men vs women is approximately 6:1
- associated with stress and stress hormones (ie, corticosteroids and epinephrine);
- individuals with a "type A personality" who are under stress
- recurrence in the ipsilateral eye is approximately 30% and CSR in the fellow eye was 32%

Central Serous Retinopathy

- systemic associations of CSCR include:
  - Sleep apnea syndrome
  - Systemic hypertension
  - Psychopharmacologic medications
  - Systemic lupus erythematosus
  - Gastroesophageal reflux disease
- Association between *H. pylori* infection, peptic ulcer disease and CSCR has been reported in some studies

Central Serous Retinopathy



Pacific University Oregon

CSR versus RD







Pacific University Oregon

Central Serous Retinopathy

- 80% to 90% of cases resolve spontaneously within 3 months
- Treatment options:
  - include laser photocoagulation,
  - Anti-VEGF
    - Results remain inconclusive, and long term benefits warrant more studies.
  - "safety-enhanced" PDT (current “preferred” treatment option)
    - PDT causes vascular remodeling of the choroid and choroidal hypoperfusion.,
  - Acetazolamide reduced the time for subjective and objective CSR resolution, but it had no effect on final VA or recurrence rate. Most patients in the experimental group in that study had side effects from the acetazolamide, including paresthesias, nervousness, and gastric upset

Pacific University Oregon

Central Serous Retinopathy

- Treatment options:
  - Topical NSAIDs:
    - Conflicting reports
    - Michael Singer, MD, from Medical Center Ophthalmology in San Antonio reported an increase in resolution time by 50%
    - PRADEEP VENKATESH, MD reports that NSAIDS treatment could possibly slow down or cause a rebound CSR

Latest Treatment Under Investigation

- Eplerenone is a mineralocorticoid antagonist receptor currently used in the treatment of hypertension and congestive heart failure.
- Literature has demonstrated improved resolution of CSR with no serious adverse effects.
- Several randomized clinical trials are currently underway.
  - Currently, its use in CSCR remains investigational and is not considered standard of care

Pacific University Oregon

Case

- 50 YR WM
- POHx: had cataract surgery in his left eye at age 25 secondary to trauma to the eye,
  - Has a mid-dilated pupil post trauma
- PMHx: no known health problems and no medications
- VA: 6/6 (20/20) OD, OS

Pacific University Oregon

Health Assessment

- SLE:
  - OD unremarkable
  - OS: mid-dilated pupil with sluggish response to light
    - PCIOL well centered and no haze
- IOP: OD 12 and OS 26 mm Hg (TAG)
    - NCT OS (31 and 23)
    - Second visit: OD: 13 and OS: 27

Pacific University Oregon

Health Assessment

- Gonioscopy:
  - OD: unremarkable
  - OS: see photo

Pacific University Oregon

Optic Nerves



OS

OD

Pacific University Oregon

Visual Fields



OS



OD

Pacific University Oregon

Ganglion Cell Analysis



Pacific University Oregon

RNFL and ONH Analysis



Pacific University Oregon

What would you diagnose your patient as having?

1. POAG
2. Narrow angle
3. Ocular hypertension
4. Angle recession
5. Angle closure
6. Neovascular glaucoma

What would you begin treatment with for this patient?

1. Travoprost (Travatan Z) qhs OS
2. Brinzolamide (Azopt) TID OS
3. Timolol BID OS
4. Brimonidine (Alphagan P) TID OS
5. Pilocarpine QID OS

Patient Update

- Patient was seen a year later
- Latanoprost qhs (remembers 5 days out of week)
- IOP’s: OD: 14 and OS: 13 mm Hg
- No change in OCT

Pacific University Oregon

The Future of Glaucoma Diagnosis and Management???

Pacific University Oregon

Normal Eye

OCT En Face



RPC



RPC Vessel density



RNFL Thickness



Images and data courtesy of Robert Weinreb, MD and Linda Zangwill, PhD, UC San Diego

Moderate Glaucoma

OCT En Face



RPC



RPC Vessel density



RNFL Thickness



Images and data courtesy of Robert Weinreb, MD and Linda Zangwill, PhD, UC San Diego

Advanced Glaucoma

OCT En Face



RPC



RPC Vessel density



RNFL Thickness



Images and data courtesy of Robert Weinreb, MD and Linda Zangwill, PhD, UC San Diego

QUICKIE

Pacific University Oregon

Identify. (Note: on red free filter these "lesions" are still visible)

1. Nevus
2. Melanoma
3. CHRPE
4. Toxoplasmosis
5. Toxocariasis





Pacific University Oregon

CHRPE vs Nevus





CHRPE vs Hamartomas





JRE 4. Retinal pigment epithelial hamartomas (pigmented ocular
lus lesions) associated with familial adenomatous polyposis
dner syndrome).

Nevi Trivia

- 31% of choroidal nevi show slight enlargement over time without the transformation to a melanoma (Ophthalmology 2011)
- The prevalence of choroidal nevi in the white U.S. population ranges from 4.6% to 7.9%
  - If it is assumed that all choroidal melanomas arise from preexisting nevi, then the published data suggest a low rate (1/8845) of malignant transformation of a choroidal nevus in the U.S. white population. (Ophthalmology 2005)
- Choroidal melanoma risk for metastasis, ranging from 16% to 53% (at 5 years of follow-up) depending on the size of the tumor at the time of diagnosis. (Arch Ophthalmol 1992)

Pacific University Oregon

TFSOM—"To Find Small Ocular Melanoma"

Thickness: lesions >2mm
Fluid: any subretinal fluid (suggestive of serous retinal detachment)
Symptoms: photopsia, vision loss
Orange pigment overlying the lesion
Margin touching optic nerve head (<3mm)

- *None* of these factors = 3% risk of a nevus converting to melanoma in five years.
  One of these factors = 8% risk of conversion in five years. *Two* or more factors = 50% risk of conversion in five years. For any changes noted during the course of follow-up, refer the patient to a retinal practice or an ocular oncology service.

Pacific University Oregon

TFSOM-UHHD:
"To Find Small Ocular Melanoma Using Helpful Hints Daily"

Thickness: lesions >2mm
Fluid: subretinal fluid

Symptoms: photopsia, vision loss

Orange pigment overlying the lesion

Margin touching optic nerve head (<3mm)

Ultrasound **H**ollowness

Halo absence

Drusen absence

- Choroidal nevi showing no features should be initially monitored twice yearly and followed up annually
- 1 or 2 features should be monitored every 4 to 6 months.
- Nevi with 3 or more features should be evaluated at an experienced center for management alternatives and possible treatment owing to the high risk of ultimate growth

Pacific University Oregon

From: **Enhanced Depth Imaging Optical Coherence Tomography of Small Choroidal Melanoma: Comparison With Choroidal Nevus**

Arch Ophthalmol. 2012;130(7):850-856. doi:10.1001/archophthalmol.2012.1135



From: **Enhanced Depth Imaging Optical Coherence Tomography of Small Choroidal Melanoma: Comparison With Choroidal Nevus**

Arch Ophthalmol. 2012;130(7):850-856. doi:10.1001/archophthalmol.2012.1135



Case

- 65 yr old white male
  - Notices spot in vision in his left eye
  - Diabetes for 15 years
- Vision:20/20 (6/6) and 20/40 (6/12)
- Dilated exam:
  - Large lesion noted in left eye (not noted in exam 6 months previously
  - See photo and B-scan





Pacific University Oregon

What is your tentative diagnosis for this patient?

1. Astrocytic hamartoma
2. Amelanotic melanoma
3. Retinoblastoma
4. Metastatic choroidal tumor

Ocular Tumors

Astrocytic Hamartoma



Amelanotic Melanoma



Retinoblastoma



Metastatic Choroidal Tumor



Where does a primary choroidal melanoma tend to metastasize too?

1. Brain
2. Breast
3. Lung
4. Liver

Pacific University Oregon

Choroidal Melanoma Metastases

- 80 to 90% of metastases from uveal melanoma occurred in the liver, less common sites being the skin and lung.
  - Gragoudas ES, Seddon JM, Egan KM, et al. Long-term results of proton beam irradiated uveal melanomas. Ophthalmology. 1987;94:349–53.

Pacific University Oregon

Melanoma and Mortality

- Tumor Size:
  - 5-year mortality after enucleation:
    - 16% for small melanoma,
    - 32% for medium melanoma, and
    - 53% for large melanoma.
  - the prognostic importance of tumor size:
    - each 1-mm increase in melanoma thickness adds approximately 5% increased risk for metastatic disease at 10 years
- Tumor genetics:
  - Chromosome monosomy 3 (apprx 50% of patients)
    - 50% of them develop metastasis within 5 years of diagnosis
    - 70% mortality within 4 years of ocular treatment
    - one of the most important independent risk factors of poor survival

Pacific University Oregon

New Treatment for Choroidal Melanoma

- light-activated AU-011 agent represents the first potential new therapy for choroidal melanoma
- AU-011 is a viral nanoparticle conjugate delivered by intravitreal injection, which targets tumor cells in the choroid and then is activated by ophthalmic laser to disrupt the tumor cell membrane, leading to necrosis.
- Two year prospective study complete

Pacific University Oregon

New Treatment for Choroidal Melanoma

- Total cohort of 36
  - 12 patients in the single-dose cohort demonstrated a modest tumor control rate of 67% with a follow-up period of 9 to 24 months, and
  - 22 patients in the multiple-dose cohort (2 patients lost to follow-up) demonstrated a modest tumor control rate of 77% with a follow-up period of 0.5 to 18 months.
  - Subjects treated with the maximum safe and tolerated dose (80 µg with 2 lasers) with 0.5 months to 6 months follow-up have a tumor control rate of 92% (13 of 14 subjects).
  - Vision was preserved in all patients at 3 months or longer up to 24 months.

Pacific University Oregon

Question

Which of the following depicts a retina undergoing hydroxychloroquine toxicity?



1 2 3 4

Pacific University Oregon

Question

Which of the following depicts a retina undergoing hydroxychloroquine toxicity?



ARMD

Macular Hole

OHS

Bull's Eye Maculopathy

Question

Which OCT goes with a patient undergoing hydroxychloroquine toxicity?

1



2



3



4



Treatment and Management: Antimalarial Ocular Complications

- *Toxicity can lead to whorl keratopathy, "bulls eye" maculopathy, retinal vessel attenuation, and optic disc pallor.*
- *Early stages of maculopathy are seen as mild stippling or mottling and reversible loss of foveal light reflex*
- *"Classic" maculopathy is in form of a "bulls eye" and is seen in later stages of toxicity*
  - *this is an irreversible damage to the retina despite discontinuation of medication*

Pacific University Oregon

Treatment and Management: Antimalarials



Bulls Eye Maculopathy



Whorl Keratopathy

Pacific University Oregon

Revised Recommendations on Screening for Retinopathy

- *2002 recommendations for screening were published by Ophthalmology*
- *Revised recommendations on screening published in Ophthalmology 2011;118:415-42*
  - *Significant changes in light of new data on the prevalence of retinal toxicity and sensitivity of new diagnostic techniques*
  - *Risk of toxicity after years of use is higher than previously believed*
    - *Risk of toxicity approaches 1% for patients who exceed 5 years of exposure*

Pacific University Oregon

“New” New Recommendations

- **Recommendations on Screening for Chloroquine and Hydroxychloroquine Retinopathy** – Ophthalmology 2016; 123:1386-1394
  - Released March 2016 from American Academy of Ophthalmology
  - revised in light of new information about the prevalence of toxicity, risk factors, fundus distribution, and effectiveness of screening tools.

Pacific University Oregon

2016 Recommendations

- maximum daily HCQ use of 5.0 mg/kg real weight, which correlates better with risk than ideal weight.
- risk of toxicity is dependent on daily dose and duration of use.
  - at recommended doses:
    - risk of toxicity up to 5 years is under 1%
    - up to 10 years is under 2%
    - rises to almost 20% after 20 years. However, even after 20 years, a patient without toxicity has only a 4% risk of converting in the subsequent year.





2016 Recommendations

- High dose and long duration of use are the most significant risks.
  - Other major factors are concomitant renal disease, or use of tamoxifen
- A baseline fundus examination should be performed to rule out preexisting maculopathy.
- Begin annual screening after 5 years for patients on acceptable doses and without major risk factors.

Pacific University Oregon

2016 Recommendations

- primary screening tests are automated visual fields plus spectral-domain optical coherence tomography (SD OCT)
- wider test patterns (24-2 or 30-2) are needed for Asian patients in whom toxicity often manifests beyond the macula. These larger patterns have only 4 central test spots, and even a single central spot of reduced sensitivity should be taken seriously.









Pacific University Oregon

Revised Recommendations on Screening for Retinopathy

- *Parafoveal loss of visual sensitivity may appear before changes are seen on fundus evaluation*
    - *Many instances where retinopathy was unrecognized for years as field changes were dismissed as "non-specific" until the damage was severe*
    - *10-2 VF should always be repeated promptly when central or parafoveal changes are observed to determine if they are repeatable*
    - *Advanced toxicity shows well-developed paracentral scotoma*

Pacific University Oregon

Paracentral Scotomas



Normal Retina: VF/OCT/ERG

TD-OCT

SD-OCT



Rodriguez-Padilla, J. A. et al. Arch Ophthalmol 2007;125:775-780.

ARCHIVES OF OPHTHALMOLOGY

PIL=PR Integrity Line

Mild Maculopathy

Normal Foveal Peak



Rodriguez-Padilla, J. A. et al. Arch Ophthalmol 2007;125:775-780.

ARCHIVES OF OPHTHALMOLOGY

Bull's Eye Maculopathy

Flattened Foveal Peak



Rodriguez-Padilla, J. A. et al. Arch Ophthalmol 2007;125:775-780.

ARCHIVES OF OPHTHALMOLOGY

Fundus photograph | Spectral domain OCT | 10-2 pattern deviation and threshold



Major Risk Factors

Table 1. Major Risk Factors for Toxic Retinopathy

Daily dosage	
HCQ	>5.0 mg/kg real weight
CQ	>2.3 mg/kg real weight
Duration of use	>5 Yrs, assuming no other risk factors
Renal disease	Subnormal glomerular filtration rate
Concomitant drugs	Tamoxifen use
Macular disease	May affect screening and susceptibility to HCQ/CQ

CQ = chloroquine; HCQ = hydroxychloroquine.

Pacific University Oregon

Screening Recommendations

Table 2. Screening Frequency

Baseline Screening
Fundus examination within first year of use
Add visual fields and SD OCT if maculopathy is present
Annual Screening
Begin after 5 yrs of use
Sooner in the presence of major risk factors

SD OCT = spectral-domain optical coherence tomography.

Pacific University Oregon

What does this look like???



Pacific University Oregon

Macular hole

- Unilateral, decreased vision
  - Often in 60-80 year old women
  - Anyone w/ a history of trauma
- Symptoms:
  - Decreased vision, metamorphopsia
    - 20/200 for full thickness holes
- Signs:
  - Red hole in the macula
  - (+) Watzke-Allen sign

Macular hole

- Stages
  - Stage 1a -> impending hole. Normal foveal depression with yellow spot/dot in fovea.
  - Stage 1b -> Abnormal foveal depression with yellow ring.



Stage 1b macular hole



Macular hole

- Stages
  - Stage 2 -> Small full-thickness hole. 20/80 - 20/400.
  - Stage 3 -> Full-thickness hole w/ cuff of SRF. No PVD
  - Stage 4 -> Full-thickness hole with cuff of SRF, with complete PVD.



Stage 2 macular hole



Macular hole

- Stages
  - Stage 2 -> Small full-thickness hole. 20/80 - 20/400.
  - Stage 3 -> Full-thickness hole w/ cuff of SRF. No PVD
  - Stage 4 -> Full-thickness hole with cuff of SRF, with complete PVD.



Stage 4 macular hole →

Stage 3 Macular hole





New Macular Hole Staging

Table 2. Correlation between Commonly Used Clinical Macular Hole Stages and the International Vitreomacular Traction Study Classification System for Vitreomacular Adhesion, Traction, and Macular Hole

Full-Thickness Macular Hole Stages in Common Use	International Vitreomacular Traction Study Classification System
Stage 0	VMA
Stage 1: impending macular hole	VMT
Stage 2: small hole	Small or medium FTMH with VMT
Stage 3: large hole	Medium or large FTMH with VMT
Stage 4: FTMH with PVD	Small, medium, or large FTMH without VMT



Pacific University Oregon

New Macular Hole Staging

Table 2. Correlation between Commonly Used Clinical Macular Hole Stages and the International Vitreomacular Traction Study Classification System for Vitreomacular Adhesion, Traction, and Macular Hole

Full-Thickness Macular Hole Stages in Common Use	International Vitreomacular Traction Study Classification System
Stage 0	VMA
Stage 1: impending macular hole	VMT
Stage 2: small hole	Small or medium FTMH with VMT
Stage 3: large hole	Medium or large FTMH with VMT
Stage 4: FTMH with PVD	Small, medium, or large FTMH without VMT



New Macular Hole Staging

Table 2. Correlation between Commonly Used Clinical Macular Hole Stages and the International Vitreomacular Traction Study Classification System for Vitreomacular Adhesion, Traction, and Macular Hole

Full-Thickness Macular Hole Stages in Common Use	International Vitreomacular Traction Study Classification System
Stage 0	VMA
Stage 1: impending macular hole	VMT
Stage 2: small hole	Small or medium FTMH with VMT
Stage 3: large hole	Medium or large FTMH with VMT
Stage 4: FTMH with PVD	Small, medium, or large FTMH without VMT

Small FTMH w/o traction



New Macular Hole Staging

Table 2. Correlation between Commonly Used Clinical Macular Hole Stages and the International Vitreomacular Traction Study Classification System for Vitreomacular Adhesion, Traction, and Macular Hole

Full-Thickness Macular Hole Stages in Common Use	International Vitreomacular Traction Study Classification System
Stage 0	VMA
Stage 1: impending macular hole	VMT
Stage 2: small hole	Small or medium FTMH with VMT
Stage 3: large hole	Medium or large FTMH with VMT
Stage 4: FTMH with PVD	Small, medium, or large FTMH without VMT

Medium FTMH w/o traction



250-400 microns

Pacific University Oregon

New Macular Hole Staging

Table 2. Correlation between Commonly Used Clinical Macular Hole Stages and the International Vitreomacular Traction Study Classification System for Vitreomacular Adhesion, Traction, and Macular Hole

Full-Thickness Macular Hole Stages in Common Use	International Vitreomacular Traction Study Classification System
Stage 0	VMA
Stage 1: impending macular hole	VMT
Stage 2: small hole	Small or medium FTMH with VMT
Stage 3: large hole	Medium or large FTMH with VMT
Stage 4: FTMH with PVD	Small, medium, or large FTMH without VMT

Large FTMH with traction



> 400 microns

Pacific University Oregon

Case

- 65 year old Caucasian patient presents with sudden onset loss/blurring of vision in the right eye
- PMHx: HTN for 15 years, takes "water pill"
- VA's: 20/60 OD, 20/25 OS
- Pupils: PERRL –APD
- CVF: Inferior defect right eye, no defects noted in the left eye

Pacific University Oregon

Question

Which of the following "pops" to the top of your differential list?

1



2



3



4



Pacific University Oregon

Vision Loss Without Pain: Diabetes/Diabetic Retinopathy

- *Microvascular complications resulting in capillary closure & abnormal permeability*
- *S&S include;*
  - *blurring of vision (maculopathy and refractive error shifts),*
  - *sudden drop in vision (vitreous heme),*
  - *dot and blot hemes,*
  - *exudate,*
  - *cotton wool spots,*
  - *neovascularization (iris, retina and disc)*

Pacific University Oregon

Diabetic Retinopathy

CSME (DME)



CSME (DME) OCTA



Pacific University Oregon

VEGF and DME


Normal retina
Retina with DME
VEGF
Macular edema


Diabetes
Microvascular damage
Metabolic response
Ischemia
VEGF
Increased permeability
Leakage
Macular edema
Neovascularization

Vision Loss Without Pain: Vein Occlusion

- *Associated with:*
  - *hypertension,*
  - *coronary artery disease,*
  - *DM and*
  - *peripheral vascular disease.*
- *Usually seen in elderly patients (60-70), slight male and hyperopic predilection.*
- *Second most common vascular disease after diabetic retinopathy.*

Pacific University Oregon

Branch Retinal Vein Occlusion: Signs/Symptoms

- *BRVO: sudden, painless, visual field defect.*
  - *patients may have normal vision.*
  - *quadrantic VF defect,*
  - *dilated tortuous retinal veins with superficial hemes and CWS*
  - *typically occurs at A/V crossing (sup/temp)*



Pacific University Oregon

BRVO

- BRVO more common than CRVO and has more favorable prognosis
  - Overall 50-60% of BRVO patients will maintain VA of 20/40 or better
- Visual loss results from:
  - Macular edema
  - Foveal hemorrhage
  - Vitreous heme
  - Epiretinal membrane
  - RD
  - Macular ischemia
  - Neovascularization complications

Pacific University Oregon



http://www.healio.com/ophthalmology/journals/osli/



Question

What would you recommend to a patient with ***a non-ischemic BRVO*** *who has decreased vision secondary to macular edema?*

1. *Monitor as will resolve on its own*
2. *Monitor for 5-6 months then macular grid laser if not resolved*
3. *Macular grid laser immediately*
4. *Monitor for 5-6 months then initiate anti-VEGF if not resolved*
5. *Initiate anti-VEGF treatment immediately*

Pacific University Oregon

Study Design (n=397) BRVO

BRAnch retinal Vein Occlusion study safety/efficacy



Mean Change from Baseline BCVA

BRVO



The gain of additional 3 lines occurred at a rate of 61% of 0.5 AVT grp, 55% for 0.3 AVT & 29% placebo

Central Retinal Vein Occlusion: Signs/Symptoms

- *CRVO: thrombus occurring at lamina is classical theory but new evidence indicates that the occlusion is typically in the optic nerve posterior to the lamina cribrosa*
  - *decreased VA ranging from near normal to hand motion with majority 20/200 range*
  - *dilated tortuous vessels, with numerous retinal hemes and CWS*



Pacific University Oregon

Central Retinal Vein Occlusion

- *Visual morbidity and blindness are primarily from:*
  - *persistent macular edema,*
  - *macular ischemia and*
  - *neovascular glaucoma*

Pacific University Oregon

Central Retinal Vein Occlusion

- CRVO's can be ischemic or non.
  - Classical definition of ischemic is 10-disc area of non-perfusion found on angiography
  - RAPD and ERG maybe better predictor
  - VA's typically worse in ischemic
  - Increased number of cotton wool spots with decreased VA maybe predictive

Pacific University Oregon

Central Retinal Vein Occlusion

- Ischemic CRVO may lead to iris neovascularization and neovascular glaucoma
  - Estimated apprx 20% of CRVO's are ischemic with 45% of those developing neo
- Regular examinations (1-2 wks) to monitor for ischemia or neo development
  - should include gonio as angle neo can precede iris rubeosis

Study Design CRUISE (n=392)

CRVO

Central Retinal vein occlUsIon Study: Efficacy & safety



Mean Change from Baseline BCVA

CRVO



Pts with >/= 3 line improvement was noted in 48% of .5 AVT, 26 of .3 AVT & 17% of sham

Vision Loss Without Pain: Artery Occlusion

- *Primarily embolic in nature from cholesterol, calcifications, plaques.*
- *Usually occurs in elderly associated with:*
  - *hypertension (67%),*
  - *carotid occlusive disease (25%),*
  - *DM (33%) and*
  - *cardiac valvular disease.*
- *Sudden loss of unilateral, painless vision*
  - *defect dependent upon location of occlusion*

Pacific University Oregon

Vision Loss Without Pain: Artery Occlusion

- *BRAO typically located in temporal retinal bifurcations.*



Pacific University Oregon

CRAO

- *CRAO has profound vision loss with history of amaurosis fugax.*
  - *Vision is usually CF (count fingers) to LP (light perception) with positive APD.*
  - *Diffuse retinal whitening with arteriole constriction, cherry red macula.*



Pacific University Oregon

Ophthalmic Emergency

- Treatment is controversial due to poor prognosis and questionable benefit.
- Treat immediately before workup, if patient presents within 24 hours of visual loss:
  - Digital ocular massage,
  - systemic acetozolamide (500 mg IV or po),
  - topical ocular hypertensive drops (Iopidine, B-blocker),
  - anterior chamber paracentesis,
  - consider admission to hospital for carbogen Tx (high carbon dioxide)

QUICKIE

Pacific University Oregon

13 YR Female

CC: noticed that her left eye became blurry and objects were “wavy” a couple of days ago. Sudden onset and she had experienced a headache over the left eye just prior to the vision going blurry.

Ocular Hx: she currently wear glasses for distance

Medical Hx: she is currently not diagnosed with any health problems and is not taking any medications

Pacific University Oregon

Entrance Skills

VA with current Rx: 20/30 OD and 20/30 OS

Entrance skills unremarkable

Amsler: metamorphopsia OS

BCVA: 20/20 OD with increased minus, no improvement possible in the left eye

IOP's: 13 mm Hg OD and OS

Fundus Photos





Pacific University Oregon

OCT





Pacific University Oregon

Question

What is your tentative diagnosis?

1. Central serous choroidopathy
2. VKH
3. Pigment epithelial detachments (PED's)
4. Diabetic retinopathy

Pacific University Oregon

Retina Consult

- Referred patient to retina and they confirmed the diagnosis of VKH.
- She was begun on oral prednisone 60 mg per day and she was re-evaluated in 1 week.
- At the follow up, there was reduction in her serous retinopathy and vision was improved.

Pacific University Oregon

From the Experts

- Vogt-Koyanagi-Harada (VKH) disease is a multisystemic disorder characterized by granulomatous panuveitis with exudative retinal detachments that is often associated with neurologic and cutaneous manifestations.
- VKH disease occurs more commonly in patients with a genetic predisposition to the disease, including those from Asian, Middle Eastern, Hispanic, and Native American populations.

From the Experts

- VKH:
  - Patients have no prior history of ocular trauma or surgery
  - Patients have no evidence of another ocular disease based on clinical or laboratory evidence
  - Patients have bilateral ocular involvement.

From the Experts

- VKH:
  - The neurologic and auditory signs include the following:
    - Malaise, fever, headache, nausea, abdominal pain, stiffness of the neck and back, or a combination of these factors; headache alone is not sufficient to meet the definition of meningitis
    - Tinnitus
    - Cerebrospinal fluid pleocytosis
  - Integumentary signs include the following:
    - Alopecia: loss of body hair
    - Poliosis: loss of pigment in hair
    - Vitiligo: loss of skin pigmentation in blotchy pattern

VKH Treatment

- For most patients with bilateral serous detachments and severe visual loss, begin therapy with systemic prednisone (1-2 mg/kg/day).
- The length of treatment and subsequent taper must be individualized for each patient.
  - Most patients require therapy for 6 months and occasionally up to 1 year before successful tapering of systemic corticosteroids.
  - Systemic therapy should not be discontinued during the 3 months following the onset of the disease because of the risk for recurrence.